Virtual Screening-Based Discovery and Mechanistic Characterization of the Acylthiourea MRT-10 Family as Smoothened Antagonists
作者:Fabrizio Manetti、Helene Faure、Hermine Roudaut、Tatiana Gorojankina、Elisabeth Traiffort、Angele Schoenfelder、Andre Mann、Antonio Solinas、Maurizio Taddei、Martial Ruat
DOI:10.1124/mol.110.065102
日期:2010.10
The seven-transmembrane receptor Smoothened (Smo) is the major component involved in signal transduction of the Hedgehog (Hh) morphogens. Smo inhibitors represent a promising alternative for the treatment of several types of cancers linked to abnormal Hh signaling. Here, on the basis of experimental data, we generated and validated a pharmacophoric model for Smo inhibitors constituted by three hydrogen bond acceptor groups and three hydrophobic regions. We used this model for the virtual screening of a library of commercially available compounds. Visual and structural criteria allowed the selection of 20 top scoring ligands, and an acylthiourea, N -(3-benzamidophenylcarbamothioyl)-3,4,5-trimethoxybenzamide (MRT-10), was identified and characterized as a Smo antagonist. The corresponding acylurea, N -(3-benzamidophenylcarbamoyl)-3,4,5-trimethoxybenzamide (MRT-14), was synthesized and shown to display, in various Hh assays, an inhibitory potency comparable to or greater than that of reference Smo antagonists cyclopamine and N -((3 S ,5 S )-1-(benzo\[ d \]\[1,3\]dioxol-5-ylmethyl)-5-(piperazine-1-carbonyl)pyrrolidin-3-yl)- N -(3-methoxybenzyl)-3,3-dimethylbutanamide (Cur61414). Focused virtual screening of the same library further identified five additional related antagonists. MRT-10 and MRT-14 constitute the first members of novel families of Smo antagonists. The described virtual screening approach is aimed at identifying novel modulators of Smo and of other G-protein coupled receptors.
七次跨膜受体Smoothened(Smo)是Hedgehog(Hh)形态发生素信号传导的主要组成部分。Smo抑制剂为治疗与异常Hh信号传导相关的几种癌症提供了一种有希望的选择。在此,基于实验数据,我们生成了并验证了一个由三个氢键受体基团和三个疏水区域组成的针对Smo抑制剂的药效模型。我们利用这个模型对一个商业可获得的化合物库进行了虚拟筛选。通过视觉和结构标准,选出了20个得分最高的配体,并鉴定和表征了一种酰基硫脲,N-(3-苯甲酰胺苯基氨基甲酰硫基)-3,4,5-三甲氧基苯甲酰胺(MRT-10),作为一种Smo拮抗剂。相应的酰基脲,N-(3-苯甲酰胺苯基氨基甲酰基)-3,4,5-三甲氧基苯甲酰胺(MRT-14)被合成,并展示在各种Hh检测中,其抑制效力与参考Smo拮抗剂环巴胺和N-((3S,5S)-1-(苯并[d][1,3]二氧杂环-5-基甲基)-5-(哌嗪-1-羰基)吡咯烷-3-基)-N-(3-甲氧基苄基)-3,3-二甲基丁酰胺(Cur61414)相当或更高。对该库的集中虚拟筛选进一步鉴定了五个额外的相关拮抗剂。MRT-10和MRT-14构成了新型Smo拮抗剂家族的首次成员。所描述的虚拟筛选方法旨在识别Smo和其他G蛋白偶联受体的新型调制因子。